Montelukast 10 mg tabs — Membership Pricing
Montelukast 10 mg tabs is not confirmed for no-additional-cost pricing. Membership pricing may be available; confirm the price with the dispensing pharmacy.
Montelukast 10 mg tabs Pricing
| Pricing type | Price |
|---|---|
| TheDrugClub | Membership pricing may be available |
| Typical Retail | $171.00 |
Membership pricing may be available; confirm the price with the dispensing pharmacy.
About Montelukast 10 mg tabs
Montelukast 10 mg tabs is a prescription medication. Ask your doctor if Montelukast 10 mg tabs is right for you.
Other strengths and forms of Montelukast
Conditions Treated with Montelukast 10 mg tabs
How to Check Montelukast 10 mg tabs Pricing
- Join TheDrugClub for $19.95/month
- Receive your member card by email
- Present your card at a participating pharmacy
- Check active-formulary eligibility or available membership pricing
Montelukast 10 mg tabs at Participating Pharmacies
- CVS Pharmacy
- Walgreens
- Walmart Pharmacy
- Rite Aid
- Kroger Pharmacy
- Costco Pharmacy
- Albertsons
- Safeway
- Publix Pharmacy
- H-E-B Pharmacy
Pharmacy participation and fulfillment options vary. Present your membership card and confirm current pricing before filling.
What Montelukast 10 mg tabs is approved for (FDA label)
SINGULAIR is a leukotriene receptor antagonist indicated for: Prophylaxis and chronic treatment of asthma in patients 12 months of age and older ( 1.1 ). Acute prevention of exercise-induced bronchoconstriction (EIB) in patients 6 years of age and older ( 1.2 ). Relief of symptoms of allergic rhinitis (AR): seasonal allergic rhinitis (SAR) in patients 2 years of age and older, and perennial allergic rhinitis (PAR) in patients 6 months of age and older. Reserve use for patients who have an inadequate response or intolerance to alternative therapies ( 1.3 ).
Source: Read the full FDA label on DailyMed. Label effective date: April 30, 2025.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Boxed warning for Montelukast 10 mg tabs (FDA label)
WARNING: SERIOUS NEUROPSYCHIATRIC EVENTS Serious neuropsychiatric (NP) events have been reported with the use of SINGULAIR. The types of events reported were highly variable, and included, but were not limited to, agitation, aggression, depression, sleep disturbances, suicidal thoughts and behavior (including suicide). The mechanisms underlying NP events associated with SINGULAIR use are currently not well understood [see Warnings and Precautions (5.1) ] . Because of the risk of NP events, the benefits of SINGULAIR may not outweigh the risks in some patients, particularly when the symptoms of disease may be mild and adequately treated with alternative therapies. Reserve use of SINGULAIR for patients with allergic rhinitis who have an inadequate response or intolerance to alternative therapies [see Indications and Usage (1.3) ] . In patients with asthma or exercise-induced bronchoconstriction, consider the benefits and risks before prescribing SINGULAIR. Discuss the benefits and risks of SINGULAIR with patients and caregivers when prescribing SINGULAIR. Advise patients and/or caregivers to be alert for changes in behavior or new NP symptoms when taking SINGULAIR. If changes in behavior are observed, or if new NP symptoms or suicidal thoughts and/or behavior occur, advise patients to discontinue SINGULAIR and contact a healthcare provider immediately [see Warnings and Precautions (5.1) ] . WARNING: SERIOUS NEUROPSYCHIATRIC EVENTS See full prescribing information for complete boxed warning. Serious neuropsychiatric events have been reported in patients taking SINGULAIR ( 5.1 ).
Source: FDA prescribing information (DailyMed). Set ID: 482dcc92-b47f-4ea6-854a-f5ac2aea7842. SPL document ID: 57a12189-3bb3-4a5d-b5fe-fc57db87c134. Label effective date: April 30, 2025. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Dosage forms and strengths for Montelukast 10 mg tabs (FDA label)
Tablets: 10 mg, beige, rounded square-shaped, film-coated tablets, with code MSD 117 on one side and SINGULAIR on the other. Chewable Tablets: 5 mg, pink, round, bi-convex-shaped, with code MSD 275 on one side and SINGULAIR on the other. Chewable Tablets: 4 mg, pink, oval, bi-convex-shaped, with code MSD 711 on one side and SINGULAIR on the other. Oral Granules: 4 mg, white granules with 500 mg net weight, packed in a child-resistant foil packet. Tablets: 10 mg ( 3 ) Chewable tablets: 5 mg and 4 mg ( 3 ) Oral granules: 4 mg ( 3 )
Source: FDA prescribing information (DailyMed). Set ID: 482dcc92-b47f-4ea6-854a-f5ac2aea7842. SPL document ID: 57a12189-3bb3-4a5d-b5fe-fc57db87c134. Label effective date: April 30, 2025. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Adverse reactions for Montelukast 10 mg tabs (FDA label)
The following clinically significant adverse reactions are described elsewhere in the labeling: Neuropsychiatric Events [see Warnings and Precautions (5.1) ] Most common adverse reactions (incidence ≥5% and greater than placebo listed in descending order of frequency): upper respiratory infection, fever, headache, pharyngitis, cough, abdominal pain, diarrhea, otitis media, influenza, rhinorrhea, sinusitis, otitis ( 6.1 ).
Source: FDA prescribing information (DailyMed). Set ID: 482dcc92-b47f-4ea6-854a-f5ac2aea7842. SPL document ID: 57a12189-3bb3-4a5d-b5fe-fc57db87c134. Label effective date: April 30, 2025. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Contraindications for Montelukast 10 mg tabs (FDA label)
SINGULAIR is contraindicated in patients with hypersensitivity to any of its components. Hypersensitivity to any component of SINGULAIR ( 4 ).
Source: FDA prescribing information (DailyMed). Set ID: 482dcc92-b47f-4ea6-854a-f5ac2aea7842. SPL document ID: 57a12189-3bb3-4a5d-b5fe-fc57db87c134. Label effective date: April 30, 2025. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Warnings and precautions for Montelukast 10 mg tabs (FDA label)
Do not prescribe SINGULAIR to treat an acute asthma attack ( 5.2 ). Advise patients to have appropriate rescue medication available ( 5.2 ). Inhaled corticosteroid may be reduced gradually. Do not abruptly substitute SINGULAIR for inhaled or oral corticosteroids ( 5.3 ). Patients with known aspirin sensitivity should continue to avoid aspirin or non-steroidal anti-inflammatory agents while taking SINGULAIR ( 5.4 ). Systemic eosinophilia, sometimes presenting with clinical features of vasculitis consistent with Churg-Strauss syndrome, has been reported. These events have been sometimes associated with the reduction of oral corticosteroid therapy ( 5.5 and 6.2 ).
Source: FDA prescribing information (DailyMed). Set ID: 482dcc92-b47f-4ea6-854a-f5ac2aea7842. SPL document ID: 57a12189-3bb3-4a5d-b5fe-fc57db87c134. Label effective date: April 30, 2025. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Drug interactions for Montelukast 10 mg tabs (FDA label)
No dose adjustment is needed when SINGULAIR is co-administered with theophylline, prednisone, prednisolone, oral contraceptives, fexofenadine, digoxin, warfarin, gemfibrozil, itraconazole, thyroid hormones, sedative hypnotics, non-steroidal anti-inflammatory agents, benzodiazepines, decongestants, and Cytochrome P450 (CYP) enzyme inducers [see Clinical Pharmacology (12.3) ].
Source: FDA prescribing information (DailyMed). Set ID: 482dcc92-b47f-4ea6-854a-f5ac2aea7842. SPL document ID: 57a12189-3bb3-4a5d-b5fe-fc57db87c134. Label effective date: April 30, 2025. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.